Literature DB >> 9498760

Inhibition of cell cycle progression by a synthetic peptide corresponding to residues 65-79 of an HLA class II sequence: functional similarities but mechanistic differences with the immunosuppressive drug rapamycin.

M L Boytim1, S C Lyu, R Jung, A M Krensky, C Clayberger.   

Abstract

A synthetic peptide corresponding to a region of the alpha1 alpha-helix of DQA03011 (DQ 65-79) inhibits the proliferation of human PBL and T cells in an allele-nonspecific manner. It blocks proliferation stimulated by anti-CD3 mAb, PHA-P, and alloantigen, but not by PMA and ionomycin. Substitution of each amino acid with serine shows that residues 66, 68, 69, 71-73, and 75-79 are critical for function. Inhibition of proliferation is long lasting and is not reversible with exogenous IL-2. The peptide can be added 24 to 48 h after stimulation and still block proliferation. The DQ 65-79 peptide does not affect expression of IL-2 or IL-2R; however, IL-2-stimulated proliferation is inhibited. Cell cycle progression is blocked at the G1/S transition, and the activity of cdk2 (cyclin-dependent kinase 2) kinase is impaired by the continued presence of p27. Although these results suggest a mechanism similar to that of rapamycin, the peptide inhibition is not reversed with FK-506, which indicates a distinct mechanism.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9498760

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  A human class II MHC-derived peptide antagonizes phosphatidylinositol 3-kinase to block IL-2 signaling.

Authors:  M L Boytim; P Lilly; K Drouvalakis; S C Lyu; R Jung; A M Krensky; C Clayberger
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

2.  Inhibition of allorecognition by a human class II MHC-derived peptide through the induction of apoptosis.

Authors:  B Murphy; C C Magee; S I Alexander; A M Waaga; H W Snoeck; J P Vella; C B Carpenter; M H Sayegh
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

3.  Polarisation of major histocompatibility complex II host genotype with pathogenesis of European Brown Hare syndrome virus.

Authors:  Christos Iacovakis; Zissis Mamuris; Katerina A Moutou; Antonia Touloudi; Anne Sofie Hammer; George Valiakos; Themis Giannoulis; Costas Stamatis; Vassiliki Spyrou; Labrini V Athanasiou; Maria Kantere; Tommy Asferg; Alexios Giannakopoulos; Charlotte M Salomonsen; Dimitrios Bogdanos; Periklis Birtsas; Liljana Petrovska; Duncan Hannant; Charalambos Billinis
Journal:  PLoS One       Date:  2013-09-19       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.